COMMUNIQUÉS West-GlobeNewswire

-
Novartis Phase III ASCLEPIOS trials demonstrate robust efficacy of ofatumumab in patients with relapsing multiple sclerosis
13/09/2019 -
Weight Watchers International, Inc. to Change its Legal Name to WW International, Inc. Following Rebranding Last Year
13/09/2019 -
Philips Global Beauty Index reveals that women want personalized beauty solutions to meet their unique needs
13/09/2019 -
Akari Therapeutics’ Nomacopan Granted U.S. Orphan Drug Designation for Bullous Pemphigoid
13/09/2019 -
Salarius Pharmaceuticals Announces Senior Leadership Changes
13/09/2019 -
Akesis Galaxy™ SRS System Receives 510(k) Clearance
13/09/2019 -
Nexstim Plc Agrees on a New Loan Repayment Schedule with Kreos
13/09/2019 -
VitalHub Announces Commencement of Second Phase of Licensing Agreement with The Salvation Army Toronto Grace Health Centre
13/09/2019 -
Todos Medical Signs Binding Term Sheet with HWH World for Network Marketing of Blood Tests for the Early Detection of Breast Cancer
13/09/2019 -
Microbot Medical Announces Outcome of Annual Meeting of Shareholders
13/09/2019 -
Adamas Pharmaceuticals Appoints Neil McFarlane as Chief Executive Officer
13/09/2019 -
Helius Medical Technologies, Inc. Announces Addition of a New PoNS™ Clinic in Quebec City, Canada
13/09/2019 -
Applied Therapeutics to Present Data Highlighting AT-001 for the Treatment of Diabetic Cardiomyopathy at the Heart Failure Society of America (HFSA) 23rd Annual Scientific Meeting
13/09/2019 -
Vectura provides update on GSK Litigation
13/09/2019 -
Orchard Therapeutics Announces Departure of Chief Commercial Officer
13/09/2019 -
Teleflex to Support Responding to Cardiac Arrest at ERC Congress 2019, in Ljubljana, Slovenia from September 19th – 21st
13/09/2019 -
Zealand Pharma increases its share capital as a consequence of exercise of employee warrants
13/09/2019 -
Atara Biotherapeutics Reports Early Findings of Potential Efficacy from Phase 1 Study of ATA188 in Patients with Progressive Multiple Sclerosis at ECTRIMS 2019
13/09/2019 -
Catalyst Pharmaceuticals, Inc. Determines Not to Proceed with Previously Announced Public Offering of Common Stock
13/09/2019
Pages